- ￥690 - 2025
- Leading Biology
- AMM15504V
- 美国
- 2025年07月15日
- WB 1:2000
- Mouse
- Human, Mouse, Rat
企业认证
相关产品推荐更多 >
![NGAL (LCN2) Mouse Monoclonal Antibody [Clone ID: LBI10G2]](https://img1.dxycdn.com/2022/0707/344/1496323853485278553-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 靶点：
KDR
- 浓度：
1 mg/ml
- 应用范围：
WB 1:2000
- 宿主：
Mouse
- 适应物种：
Human, Mouse, Rat
- 保质期：
1-2年
- 供应商：
安诺伦（北京）生物科技有限公司
- 标记物：
Unconjugated
- 克隆性：
Monoclonal Antibody
- 保存条件：
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
- 形态：
PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.
- 亚型：
IgG2a
- 免疫原：
Human recombinant protein fragment corresponding to amino acids 786-1356 of human KDR (NP_002244) produced in HEK293T cell.
- 规格：
100 ul/30 ul
| 规格： | 100 ul | 产品价格： | ￥2025.0 |
|---|---|---|---|
| 规格： | 30 ul | 产品价格： | ￥690.0 |
产品概述：KDR mouse monoclonal antibody, clone LBI2A1
总结：Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009]
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
PriCells: Primary cells culture with supplement of vascular endothelial growth factor (VEGF)
, move, or further differentiate. Hence, VEGF is a potential target for the treatment of cancer. The first anti-VEGF drug, a monoclonal antibody named bevacizumab, was approved in 2004. Approximately 10-15% of patients benefit from bevacizumab therapy; however, biomarkers
. We isolated a variant of Herceptin, a therapeutic monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), on the basis of its ability to simultaneously interact with vascular endothelial growth factor (VEGF). Crystallographic
技术资料暂无技术资料 索取技术资料
